MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjd/ljaf305

Медицинская библиотека · The British journal of dermatology · 2025

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial.

Paller Amy S, Fiorillo Loretta, Becker Emily, Armesto Susana, Kontzias Apostolos, Oberoi Rajneet K, Zhang Wendy, Amouzadeh Hamid, Zhang Zuoshun, Arkin Lisa

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Oral treatment options for paediatric patients with moderate-to-severe plaque psoriasis are limited. In the 16-week double-blind placebo-controlled phase of the SPROUT trial, apremilast demonstrated efficacy vs. placebo in paediatric patients with psoriasis.

OBJECTIVES

To evaluate the 52-week efficacy and safety of apremilast in SPROUT.

METHODS

SPROUT was a phase III multicentre randomized double-blind placebo-controlled parallel-group study (NCT03701763). Patients were randomized 2 : 1 to receive apremilast 20 or 30 mg (for patients weighing 20 to < 50 kg or ≥ 50 kg at baseline, respectively) twice daily or placebo for 16 weeks, after which all patients received apremilast through week 52 (apremilast/apremilast or placebo/apremilast, respectively). Patients were aged 6-17 years and had moderate-to-severe psoriasis that was inadequately controlled by or intolerant to topical therapy.

RESULTS

Of 245 patients randomized, 221 (apremilast/apremilast, n = 149; placebo/apremilast, n = 72) entered the apremilast extension phase and 186 (apremilast/apremilast, n = 125; placebo/apremilast, n = 61) completed 52 weeks. With continued apremilast treatment, rates of static Physician Global Assessment (sPGA) response (score of 0 or 1 with ≥ 2-point reduction from baseline) further improved from week 16 (30.1%) to week 52 (47.7%). In the placebo/apremilast group, sPGA response rates increased from 9.8% at week 16 to 44.4% at week 52. The proportions of patients with ≥ 75% reduction from baseline in Psoriasis Area and Severity Index increased from 42.3% at week 16 to 60.4% at week 52 in the apremilast/apremilast group and from 13.4% to 63.9% in the placebo/apremilast group. No new safety signals were observed.

CONCLUSIONS

Improvements in clinical outcomes were sustained through 52 weeks with apremilast treatment in paediatric patients with moderate-to-severe psoriasis. Safety findings were consistent with the known safety profile.

Для цитирования: Paller Amy S, Fiorillo Loretta, Becker Emily, Armesto Susana, Kontzias Apostolos, Oberoi Rajneet K, Zhang Wendy, Amouzadeh Hamid, Zhang Zuoshun, Arkin Lisa. Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial.. The British journal of dermatology. 2025. DOI: 10.1093/bjd/ljaf305.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.